The test, created by scientists from Northwestern Medicine and the University of Chicago, identify if a patient with lymphoma will relapse after receiving treatment, predicting their survival time.
On a molecular level, the test identifies the type of tumour the patient is suffering, indicating how long the patient might live or respond to treatment in a better way.
Northwestern University Feinberg School of Medicine associate professor of cancer epidemiology and prevention Wei Zhang said: “Lymphoma represents an increasingly important health issue in the United States, so developing novel approaches for precise care of these patients will improve patients’ clinical outcomes and life quality.”
